Raymond James Financial Inc. Buys Shares of 92,347 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Raymond James Financial Inc. purchased a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 92,347 shares of the specialty pharmaceutical company's stock, valued at approximately $11,373,000. Raymond James Financial Inc. owned approximately 0.15% of Jazz Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Proficio Capital Partners LLC acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth about $4,762,000. M&T Bank Corp increased its position in Jazz Pharmaceuticals by 6.9% during the 4th quarter. M&T Bank Corp now owns 3,835 shares of the specialty pharmaceutical company's stock worth $473,000 after purchasing an additional 246 shares in the last quarter. Atria Investments Inc lifted its stake in Jazz Pharmaceuticals by 19.5% in the 4th quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company's stock valued at $336,000 after purchasing an additional 445 shares during the last quarter. Victory Capital Management Inc. boosted its position in Jazz Pharmaceuticals by 3.7% in the fourth quarter. Victory Capital Management Inc. now owns 262,689 shares of the specialty pharmaceutical company's stock valued at $32,350,000 after buying an additional 9,390 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 15.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 615,517 shares of the specialty pharmaceutical company's stock worth $75,801,000 after buying an additional 83,807 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insiders Place Their Bets

In other news, CAO Patricia Carr sold 1,140 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the sale, the chief accounting officer now owns 7,012 shares in the company, valued at $966,323.72. This trade represents a 13.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the transaction, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,736 shares of company stock valued at $4,022,825. Company insiders own 4.20% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on JAZZ shares. Royal Bank of Canada dropped their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Truist Financial increased their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. HC Wainwright upped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Finally, UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $145.00 to $179.00 in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $187.71.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock traded up $3.26 during trading hours on Monday, hitting $142.02. 969,006 shares of the company's stock traded hands, compared to its average volume of 856,356. The company has a fifty day simple moving average of $131.41 and a 200-day simple moving average of $121.79. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market capitalization of $8.63 billion, a price-to-earnings ratio of 20.00, a PEG ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.